Figure 6
EmTh-1 plus CRCL immunotherapy induces tumor-specific immunity. Naive BALB/c mice were injected with 5 × 103 12B1 cells (subcutaneously in the right groin) on day 0 and vaccinated as described in the legend to Figure 5. Surviving tumor-free mice were then rechallenged with 5 × 103 12B1 cells given subcutaneously in the right groin and 1 × 106 A20 cells given subcutaneously in the left groin on day 45. Tumor volume was determined every other day. (A) A20 tumor volume monitored in control mice; (B) A20 tumor volume monitored in emTh-1 plus CRCL-treated mice; (C) 12B1 volume monitored in control group; (D) 12B1 tumor volume monitored in emTh-1 plus CRCL-treated animals. Results are representative of 2 independent experiments.
